GLP-1 Learning Hub
Selected articles, videos and research on GLP-1 treatment, with AI-written summaries.
OriginalGila11/1/2026
Retatrutide vs Semaglutide: What the TRANSCEND-T2D-2 Head-to-Head Trial Is Built to Test
When a new medicine is set against one you already know, the first question is usually: is it better? For retatrutide, which is still investigational, and semaglutide, the honest starting point is the trial design itself. This page explains what the head-to-head study measures and what it cannot tell you.
Read more
OriginalGila11/1/2026
Vitamin B12 and other nutrients on GLP-1 medication: what is known, and what is not
When the medication quiets your appetite, the plate gets smaller. For many people, that is the relief they were hoping for. It also raises a fair question: if you are eating less, are you still getting enough of the vitamins and minerals your body runs on?
Read more
OriginalGila11/1/2026
What the Oura and UC San Diego Health GLP-1 Study Will Measure, and What Your Wearable Can Show You Now
If you started a GLP-1 medication and you already wear a ring or a watch, you have probably wondered whether all that sleep and heart rate data means anything for your journey. It is a fair question, and it is one researchers are now setting out to study. No results exist yet: the trial is not yet recruiting.
Read moreOriginalGila11/1/2026
GLP-1 medicines: frequently asked questions
Who GLP-1 medicines are for, which checks come before starting, how the medicine is used, what is monitored during treatment, how much weight people lost on average in studies, and what happens when you stop. General-information answers, with sources.
Read moreOriginalGila11/1/2026
Gallstones on GLP-1 medicines: why the risk rises and how to protect yourself
Rapid weight loss and GLP-1 medicines can raise the risk of gallstones. Regular meals, a little healthy fat in meals, fiber-rich foods, enough water and a steady pace of weight loss help lower the risk. This article also covers the symptoms that mean you should see a doctor without waiting.
Read more
OriginalGila10/18/2026
Food Tastes Different Now: What the Label Says, and Where the Studies Disagree
Taste disturbance is listed in the product information for these medicines as a change in the way food or drink tastes. What it is, research has not settled: a large records study found it recorded more often, a sensory study measured it worse, the only randomised trial found it better. The consistent part is timing.
Read more
OriginalGila10/18/2026
No Appetite on GLP-1: The Meals That Quietly Disappear
Appetite can fall so far that meals stop happening, not shrinking. On the weight-management labels that drop is the described mechanism, not a side effect, and no label states a threshold for missed meals. What they do give is a fluid warning - plus the clock, the blank in the log, and what goes short besides protein.
Read more
OriginalGila10/18/2026
Food Noise, Named and Counted: What One National Survey Actually Found
The phrase came from patients and journalists, not a clinic. In a nationally representative survey of 1,000 US adults, about half said they experience food noise sometimes or more often, and nearly one in five often or always. There is still no clinical definition and no validated cut-off.
Read more
OriginalGila10/6/2026
Shopping and Cooking on GLP-1: When the Household Still Eats
You eat a fraction of what you used to; nobody you live with has changed. In a US household panel, grocery spending fell 5.3% within six months. In a 505-person US survey, a quarter agreed they waste more food. The fix is one meal served two sizes - never a separate plate, never a cleared one.
Read more
OriginalGila10/6/2026
GLP-1 and Sleep: What the Labels and the Studies Actually Say
Insomnia is listed as a common side effect on one GLP-1 label — liraglutide, mainly in the first three months — and on none of the weekly medicines. This piece reports what the product information and two small uncontrolled studies show, why none of it proves cause, and the sleep routine you can control and log.
Read more
OriginalGila10/6/2026
Hunger Between Doses: What Is Known, and What Nobody Has Measured
The half-lives are label-established; the day-by-day story is not. We ran 18 literature searches and found no study measuring hunger, food noise or energy across the days between weekly doses. What the labels do and do not say, why people differ, and how to keep a log that shows your own week.
Read more
OriginalGila9/22/2026
Traveling with GLP-1: Pens, Flights and Your Routine
Planning a trip with your GLP-1? This essential guide helps you confidently navigate everything from understanding your pen's storage limits and breezing through airport security, to strategically packing small habits. We love how it turns coming home into a perfect opportunity to intentionally rebuild your routine, keeping your progress strong!
Read more
OriginalGila9/22/2026
Eating Out on GLP-1: Restaurants and Social Meals
Eating out on GLP-1 can feel like a challenge, and our latest article reveals it's a documented effect of social eating, not a personal failing! We arm you with smart strategies – from pre-planning your order to having a friendly comeback for "just one more" – so you can enjoy every social meal with confidence and ease.
Read more
OriginalGila9/22/2026
GLP-1 Hydration: Why Drinking Enough Gets Harder
On GLP-1s, staying properly hydrated is a double challenge – less water from food and potential fluid loss from side effects. Don't wait for thirst! Let's proactively build a routine by tying water intake to your existing daily habits, safeguarding your health and keeping you energized!
Read more
OriginalGila9/14/2026
Shotsy vs GlucoPal: How These Two GLP-1 Trackers Compare in 2026
Shotsy and GlucoPal are both free-to-download GLP-1 dose trackers rated 4.8 stars. Shotsy runs on iPhone and Android in 17 languages; GlucoPal is iPhone-only but adds AI meal-photo scanning and a published Pro price. The detail most comparisons miss: Shotsy's Android build requires Google Sign-In.
Read more
OriginalGila7/27/2026
Three GLP-1 changes your scale can't show. A body check-in shows two.
Your scale is a guide, but brilliant new research confirms it's just one piece of the GLP-1 puzzle – showing us that hair, muscle, and bone health are also transforming! This means we can empower ourselves by adding a quick weekly body check-in to truly notice and track these vital signals, giving you and your healthcare team the full picture of your incredible progress.
Read more
OriginalGila7/17/2026
For the First Time in a Decade, the Curve Is Bending
Gallup says the U.S. adult obesity rate eased from a 2022 record (39.9%) to 36.4% this year, alongside record GLP-1 use. It's self-reported, not clinically measured — and the government's own measured survey just found record obesity in teenagers. Early signal, not a verdict. What holds it is what people build, not the prescription.
Read more
OriginalGila7/17/2026
Medicare's new GLP-1 coverage: who it's actually for
Medicare's GLP-1 Bridge went live July 1 — $50/month for Wegovy, Zepbound, and Foundayo. Here's exactly who qualifies, what it doesn't cover, and why two states are pulling back the same summer.
Read more
OriginalGila7/17/2026
The 'Hungry Gut' Study, Explained: The Science Behind Food Noise
Mayo Clinic just dropped a game-changer: for a quarter of us, that constant 'food noise' and early hunger? It's your gut chemistry, producing fewer fullness hormones right at the source! This study proves it's biology, NOT a personal failing, validating so much of what we experience on this journey!
Read more
OriginalGila7/12/2026
After the Loss: What Actually Happens in Maintenance
A 2026 Oxford meta-analysis found weight regain after stopping a GLP-1 runs almost four times faster than after a lifestyle-only program — yet in real-world Cleveland Clinic data, people who kept some structure in place mostly held their loss, and 45% kept losing or stayed steady. The gap between those two numbers is the behavior layer: what people did next. A look at what maintenance actually takes after the medication stops.
Read more
OriginalGila7/12/2026
Oral GLP-1s Just Went Mainstream: Inside the Pill Era
Oral Wegovy passed 3 million prescriptions in five months, Lilly's Foundayo is scaling fast behind it, and Medicare's new Bridge program now covers GLP-1 pills for a flat $50/month. Novo's market research says Medicare patients prefer the pill roughly 2-to-1 over the shot. Here's the month the pill became a main door into GLP-1 therapy — and what a daily pill changes about the routine.
Read more
ArticleGila6/17/2026
Stopping and Restarting GLP-1 Is Normal — Here's What Holds the Loss
New data from ENDO 2026 reveals that stopping and restarting GLP-1 medication is a common chapter for many, not a failure! This isn't about perfection, but about realizing that what truly anchors your weight loss through any pause are the powerful habits you build. So, let's use this window to focus on creating a sustainable foundation that outlasts any prescription!
Read more
ArticleGila6/17/2026
GLP-1 Persistence Statistics 2026: The Start-and-Stop Numbers, Honestly
GLP-1 persistence statistics for 2026, read honestly: how many people stop (about 4 in 10 in year one), how many restart (most of them), why they pause, and the behavior layer that separates regain from kept loss. Every figure linked to a primary source.
Read more
ArticleGila6/17/2026
Moving Less on GLP-1: The Activity Drop Nobody Warns You About
A 2026 study using Fitbit data found people on GLP-1s moved less, not more — daily steps fell from 5,047 to 4,487. Here's why your body quietly slows down when you eat less, and the gentle way to protect muscle with movement and enough protein.
Read more
ArticleGila6/13/2026
Food Noise and the Win Beyond the Scale
Our latest insights reveal that for many, the true superpower of GLP-1s isn't just weight loss, but the incredible peace that comes from the "food noise" finally going quiet. This mental freedom, backed by emerging science on brain reward pathways, is a profound non-scale victory that transforms daily life and deserves every bit of celebration!
Read more
ArticleGila6/13/2026
The Things a Tracker Can't Measure
On a GLP-1, your hunger and fullness signals are changing, which makes relearning to listen to your own body a quiet superpower. This piece reframes the scale and trackers as companions, not verdicts, and names the non-scale victories data can't see.
Read more
ArticleGila6/13/2026
Do GLP-1s Change Your Personality? What the Mood Science Says
GLP-1 receptors sit in brain reward areas, mostly mapped in animal studies. An 80-trial analysis found no rise in psychiatric side effects, and FDA and EMA reviews found no link to suicidal thoughts, while a few case reports describe feeling flat. What is known, what isn't, and when to tell your prescriber.
Read more
ArticleGila6/10/2026
ADA 2026 Scientific Sessions: The GLP-1 Data That Matters
The 2026 ADA Scientific Sessions delivered the GLP-1 era's biggest weight-loss number yet — retatrutide at about 28% — plus the first oral GLP-1 to beat semaglutide and three new contenders. Here is what actually landed, what is still investigational, and what it means for your journey.
Read more
ArticleGila5/28/2026
Generic Semaglutide Spreads: The Hims & Hers Canada Signal
Hims & Hers launched generic semaglutide in Canada for about $107 USD a month after Novo Nordisk lost its Canadian patent. It's a preview of post-patent GLP-1 pricing — and a reminder of why a true generic is still years away in the US. What the launch signals for 2026.
Read more
ArticleGila5/28/2026
Retatrutide Phase 3 Results: 30% Weight Loss and the Asterisk
Eli Lilly's triple agonist retatrutide posted its first Phase 3 results: roughly 25-28% mean weight loss at 80 weeks, with 45% of high-dose participants losing over 30% of body weight. The asterisk: an 11.3% side-effect discontinuation rate. What TRIUMPH-1 means if you're on a GLP-1 now.
Read more
OriginalGila5/28/2026
GLP-1 Weight Loss Statistics: The 2026 Numbers That Matter
While the latest stats show incredible weight loss potential with new meds like Retatrutide reaching up to 28% mean loss, the quiet but crucial number is persistence. Remember, the medication opens a powerful window, but it's the habits and support you build around it that truly determine your long-term success, helping you beat the high discontinuation rates and make those amazing trial results a reality for your journey!
Read more
ArticleGila5/25/2026
The GLP-1 Stigma Paradox — Rice Study Finds Medication Users Judged More Harshly Than Non-Losers
A powerful new Rice University study confirms what many of you have likely felt: GLP-1 users face more judgment, even compared to those who don't lose weight! This isn't just about external perceptions; it's a call for us to proudly own the real, hard work you're putting into your health, despite the unfair narrative.
Read more
ArticleGila5/25/2026
FDA 503B Comment Deadline Is June 29 — What Compounded GLP-1 Users Should Do Now
The FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closes June 29, 2026. If finalized, most $200-400/month telehealth compounded GLP-1 paths close. Here's what changes, what doesn't, and what to do this month.
Read more
ArticleGila5/25/2026
Medicare GLP-1 Bridge — What the $50 Copay Pilot Actually Covers (2026)
Medicare will pay $50/month for Wegovy, Zepbound KwikPen, and Foundayo from July 1, 2026 through December 31, 2027. Eligibility is BMI-anchored at therapy initiation, not today. The $50 doesn't count toward Part D deductible or the $2,100 out-of-pocket cap. Here's exactly who qualifies and what the fine print costs.
Read more
ArticleGila5/20/2026
Is Ozempic the 'Easy Way Out'? The Truth About GLP-1 Stigma
A 2026 Rice University study found people judge GLP-1 users more harshly than those who lost no weight at all. Here is what the research shows about the 'easy way out' myth — and why a GLP-1 is a tool, not a shortcut you should hide.
Read more
OriginalGila5/13/2026
GLP-1 and Muscle Mass: What the 2025-2026 Research Actually Says
Roughly 30% of the weight lost on GLP-1 therapy is lean tissue, per a nine-trial meta-analysis. And the 2026 bone evidence points both ways at once.
Read more
OriginalGila5/13/2026
The Best Free GLP-1 Tracker Apps for Android in 2026
Seven free-or-freemium GLP-1 tracker apps on Google Play, ranked honestly. Shotsy is the strongest truly-free option (4.5 stars, 7K reviews). MyFitnessPal added free GLP-1 Support in April 2026. Plus: the Android-only Health Connect advantage iPhone users don't get.
Read more
OriginalGila5/13/2026
CagriSema vs Tirzepatide: The 22.7% Headline (and the Asterisk Nobody Mentions)
Novo Nordisk's CagriSema produced 20.4% weight loss in REDEFINE 1 (22.7% among people who stayed on treatment) — but lost head-to-head to tirzepatide in REDEFINE 4, February 2026. FDA decision late 2026. Here's why patients on Mounjaro shouldn't wait.
Read more
OriginalGila5/9/2026
Retatrutide vs Tirzepatide: The Reta Hype, Tested (2026)
Lilly's investigational triple-agonist, Retatrutide, is showing jaw-dropping ~24% weight loss in trials, potentially outpacing Tirzepatide! While the numbers are exciting and hint at the future, remember this crucial truth: the real, lasting success on any medication comes from building those rock-solid habits that support you long-term, because sustained results are about more than just the scale.
Read more
OriginalGila5/9/2026
Foundayo vs Wegovy vs Zepbound: The 2026 Oral GLP-1 Decision Guide
Get ready for an exciting new landscape in oral GLP-1s! Our latest update reveals Foundayo (orforglipron) as the ultimate winner for convenience, offering the first daily pill with absolutely no food or water restrictions, making adherence a breeze. While injectable Zepbound still leads for maximum weight loss, we now have amazing new options to consider based on your lifestyle, desired weight loss, and budget, proving your journey is more personalized than ever.
Read more
ArticleGila4/30/2026
Compounded GLP-1s in 2026: What FDA's April 30 Proposal Means for 503B and 503A Patients
The FDA just proposed changes that could impact compounded GLP-1 access from 503B facilities by 2026. This isn't immediate, but it's a call to action: connect with your prescriber now to proactively plan your transition to approved medications, ensuring your incredible progress continues seamlessly. Remember, your habits are your superpower, and we'll navigate any shifts together!
Read more
ArticleGila4/27/2026
GLP-1 Adherence Statistics 2026: Why Persistence Nearly Doubled
12-month persistence on weight-loss GLP-1s climbed from 33% in 2021 to 63% in 2024. Inside the latest Prime Therapeutics, KFF, and NEJM data — what the new numbers actually say about who stays on therapy, who stops, and why.
Read more
OriginalGila4/24/2026
The Best Free GLP-1 Tracker Apps for iPhone in 2026
Most free GLP-1 apps are freemium — the essentials are free but the useful stuff hides behind a paywall. A few are genuinely free. Here are the best free and meaningfully free GLP-1 tracker apps for iPhone in 2026, plus what still is not worth paying for.
Read more
ArticleGila4/24/2026
The Hidden GLP-1 Side Effects Clinical Trials Missed (Penn Study)
A groundbreaking Penn study used AI to analyze over 400,000 Reddit posts, uncovering GLP-1 side effects like irregular cycles and temperature changes that clinical trials often miss. This incredible research validates that if you're experiencing something "different," you're not alone, and your unique journey is helping us understand these medications even better!
Read more
ArticleGila4/18/2026
Mounjaro vs Ozempic vs Zepbound vs Wegovy (2026): The Honest Comparison
Four drugs, two active ingredients. In the one head-to-head trial in adults with obesity (SURMOUNT-5), tirzepatide averaged 20.2% weight loss at 72 weeks and semaglutide 13.7%. A clinically-honest breakdown across efficacy, side effects, cost, insurance, availability, and the lived experience — plus which one is probably right for you.
Read more
ArticleGila4/18/2026
Zepbound Side Effects Month-by-Month: The Real Timeline From Clinical Data
Most Zepbound side effects peak during dose escalation and fade within 2-4 weeks at each stable dose. Here is the month-by-month timeline from SURMOUNT clinical data — what to expect at 2.5mg, 5mg, 7.5mg, and higher doses, plus when to call your prescriber.
Read more
ArticleGila4/18/2026
Restarting Your GLP-1 After Quitting: What the 2026 Research Actually Says
New research reveals many people pause their GLP-1 journey, making restarting a common and powerful decision. This isn't a setback; it's an opportunity to learn from your initial experience and strategically recalibrate with your prescriber for durable, long-term success. Think of it as a new, informed chapter in your health journey!
Read more
ArticleGila4/13/2026
Ozempic Not Working Anymore? Why Your Medication Feels Different After Months
If you are 6 to 9 months into Ozempic and the medication has started feeling less effective, you are not imagining it and you are not broken. Three causes account for most of these reports: metabolic recalibration as your body adjusts to a smaller mass, behavioral drift as appetite habits quietly rebuild around the medication, and missed or late doses. Here is what to actually check before escalating dose or switching to Mounjaro or Zepbound.
Read more
ArticleGila4/13/2026
GLP-1 vs Intermittent Fasting: Why Stacking Them Backfires (2026 Research)
Intermittent fasting alone produces 1-3% weight loss in trials. GLP-1 medications produce 15-22%. Stacking them rarely accelerates results and often increases muscle-loss risk. Here is what the 2026 research actually shows, why the food-noise paradox matters, and what to focus on instead.
Read more
ArticleGila4/8/2026
I Tested 8 GLP-1 Tracker Apps. None of Them Build Habits.
Shotsy vs GlucoPal vs 6 more: I tested 8 GLP-1 tracker apps for 2026 — the best free options for iPhone, which are just logs, and the two that actually help you build habits. Free vs paid picks and a real-search FAQ.
Read more
OriginalGila4/6/2026
$14 a Month Semaglutide Is Real. Why You Probably Still Cannot Get It.
Generic semaglutide launched in India at $14/month on March 20, 2026. Foundayo entered the US at $149/month. Medicare added obesity coverage via the BALANCE Model. Here is what generic GLP-1 access actually means in 2026 — and why US generic Ozempic is still 5+ years away.
Read more
OriginalGila4/6/2026
GLP-1s and Existing Depression or Anxiety: What the Swedish Study Actually Found
A 2026 Lancet Psychiatry study followed people in Sweden who already had depression or anxiety and were taking diabetes medication. During semaglutide use, their illness was less likely to get worse. It was observational and did not study prevention in the general population.
Read more
OriginalGila4/6/2026
Wegovy HD Approved: What the Higher 7.2mg Dose Means for Your Journey
The FDA approved Wegovy HD (semaglutide 7.2mg) on March 19, 2026. In the STEP UP trial, 7.2mg averaged 18.7% weight loss vs 15.6% with standard 2.4mg (20.7% vs 17.5% among people who stayed on treatment). Designed for adults already tolerating the standard dose who need additional weight reduction. Available April 2026 as a single-dose pen.
Read more
OriginalGila4/6/2026
Are Your GLP-1 Habits Strong Enough? Take This Free Self-Assessment
A free 10-question self-reflection quiz to explore how strong your daily habits are on your GLP-1 journey. Not a clinical test — a gentle mirror for where you are and where to focus next.
Read more
OriginalGila4/6/2026
Stopping Ozempic Cold Turkey: What the Research Actually Says (2026)
Thinking about stopping your GLP-1 medication abruptly? Research shows 67% of weight is regained within 12 months. Here is what happens to your body and how to taper safely.
Read more
OriginalGila4/6/2026
Orforglipron Approved: Lilly's GLP-1 Pill Is Here — What It Means for Your Journey
The FDA approved orforglipron — Eli Lilly's once-daily GLP-1 pill — on April 1, 2026. No injections needed. Here's what it means for people on or considering GLP-1 medications.
Read more
OriginalGila3/30/2026
400,000 People Took the Wegovy Pill in 10 Weeks. Here Is What That Means for You.
Novo Nordisk reports 400,000 Americans started oral Wegovy in 10 weeks — the fastest US drug launch in history. At $675/month list price (50% below the injection) and $499 with the savings card, the pill broke the cost barrier for first-time patients. Here is what the launch reveals and what it means for your access.
Read more
OriginalGila3/30/2026
GLP-1 Gastroparesis: What the Research Actually Says About Stomach Paralysis Risk
GLP-1 gastroparesis risk explained with real data. The JAMA study found a 3.67x increased risk — here's what that actually means for you, who's most at risk, and what to watch for.
Read more
ArticleGila3/22/2026
Oral GLP-1 Pills Are Here: What You Need to Know
FDA approved the first oral GLP-1 pill for weight loss. Compare pills vs injections — efficacy, convenience, cost, and who they work best for.
Read more
ArticleGila3/22/2026
GLP-1s Are Tools, Not Solutions: Building What Lasts
This Gila article powerfully reminds us that GLP-1s are an incredible window of opportunity, not a permanent solution. Let's use this precious time to intentionally build lasting habits and a strong identity as someone who prioritizes their health, because what you build now is what truly persists beyond the medication.
Read more
ArticleGila3/22/2026
The FDA Warned 30 GLP-1 Telehealth Companies. Is Yours on the List?
The FDA warned 30 telehealth companies selling unapproved GLP-1 medications. If you order Ozempic, Wegovy, or compounded semaglutide online, here is how to verify your source is safe — and the red flags that mean you should stop ordering immediately.
Read more
ArticleGila3/22/2026
GLP-1 Hair Loss: What the 2026 Research Actually Found
A July 2026 BMJ study found a 37% higher alopecia rate on GLP-1s than SGLT-2 drugs. What the evidence supports, what it does not, and why month three matters.
Read more
ArticleGila3/22/2026
Ozempic Face: What It Is and What You Can Do
Ozempic face explained: what causes facial volume loss on GLP-1 medications, why rate of weight loss matters, and practical steps to protect your appearance.
Read more
ArticleGila3/22/2026
How Much Do GLP-1 Medications Cost Without Insurance?
GLP-1 medication cost without insurance: Ozempic, Wegovy, Mounjaro, and Zepbound prices, savings programs, and ways to reduce your monthly cost.
Read more
ArticleGila3/22/2026
Alcohol and GLP-1 Medications: What to Know
Drinking on Ozempic or Mounjaro? Learn how GLP-1 medications change alcohol tolerance, why many people drink less, and practical guidelines for your safety.
Read more
ArticleGila3/22/2026
Exercise on GLP-1 Medications: A Complete Guide
Working out on Ozempic or GLP-1 medication? A complete exercise guide covering resistance training, cardio, energy management, and realistic starting points.
Read more
ArticleGila3/22/2026
Managing Constipation on GLP-1 Medications
Constipation on Ozempic or Mounjaro? Learn why GLP-1 medications cause constipation, proven remedies that work, and when to talk to your doctor.
Read more
ArticleGila3/22/2026
Ozempic vs Mounjaro: Which GLP-1 Is Right for You?
Ozempic vs Mounjaro: compare semaglutide and tirzepatide side by side. Weight loss data, side effects, dosing, cost, and which GLP-1 may suit your needs.
Read more
ArticleGila3/22/2026
GLP-1 Weight Loss Plateau: Why It Happens and How to Break Through
Hit a weight loss plateau on Ozempic, Wegovy, or Mounjaro? Metabolic adaptation is the most common cause. Here are 6 evidence-based strategies to restart your progress.
Read more
ArticleGila3/22/2026
GLP-1 and Mental Health: What's Documented About Mood and Anxiety
What FDA and EMA reviews, clinical trials and adverse-event reports show about GLP-1 medications, mood, anxiety and suicidal thoughts: regulators found no evidence of a causal link, report databases still show a signal, and where to get help if you are struggling.
Read more
ArticleGila3/22/2026
Ozempic Stopped Working? 5 Real Reasons and What to Do Next (2026)
Ozempic plateau? Here are the 5 evidence-based reasons your GLP-1 medication stalled — metabolic adaptation, receptor desensitization, behavioral drift, injection site issues, and stress — plus exactly what to do about each one.
Read more
ArticleGila3/22/2026
First Month on GLP-1s: Side Effects and What to Expect
Week-by-week guide to your first month on Ozempic, Wegovy, or Mounjaro. Common side effects, timelines, coping strategies, and when to call your doctor.
Read more
ArticleGila3/22/2026
Weight Regain After Stopping GLP-1s: What Research Shows
Research shows two-thirds of weight is regained after stopping GLP-1 medication. Learn what protects against regain and how to keep your progress.
Read more
ArticleGila3/22/2026
Prevent Muscle Loss on GLP-1s: Protein and Exercise Guide
Up to 40% of GLP-1 weight loss can be muscle. Learn protein targets, resistance training basics, and body composition strategies to preserve lean mass.
Read more
ArticleGila3/22/2026
GLP-1 Nausea Relief: 8 Remedies That Actually Work (2026 Guide)
Nausea is the most common GLP-1 side effect, affecting up to 44% of users. These 8 evidence-based remedies — from meal timing to ginger to dose adjustment — can help you manage it without quitting.
Read more
ArticleGila3/22/2026
What to Eat on Ozempic and Wegovy: Nutrition Guide
Practical nutrition guide for Ozempic and Wegovy users. Learn protein targets, hydration needs, and how to nourish your body when appetite is suppressed.
Read more
OriginalGila3/12/2026
GLP-1 Community Stories: You Are Not Alone
Real stories from people on Ozempic, Wegovy, and Mounjaro. Side effects, identity shifts, food grief, and the power of community support.
Read more
OriginalGila3/12/2026
GLP-1 Habits That Last After You Stop Medication
Build lasting habits while on GLP-1 medication. Five evidence-based strategies for anchor meals, movement, and identity work that outlast your prescription.
Read more
OriginalGila3/12/2026
Food Noise on GLP-1s: What It Is and How to Navigate It
Food noise is the constant mental chatter about eating. Learn why GLP-1 medications quiet it, what happens when it returns, and how to build lasting change.
Read more
OriginalGila3/12/2026
Why So Many People Quit GLP-1s: Causes and Solutions
Persistence data shows many people stop GLP-1s within 12 months. Discover why people quit Ozempic and three actionable steps to stay on track.
Read more
ArticleMatt — Gila3/9/2026
Building Habits That Outlast Your Prescription
Your GLP-1 medication opens a window for behavior change — this guide shows you what to build inside it. Covers 16 clinically-corroborated practices organized into actionable categories: morning hydration anchors, post-meal walks, protein-first eating, strength training for lean mass preservation, food noise defense through environmental design, sleep consistency, weekly self-assessment, side effect management protocols, and structured clinician communication. Every practice backed by PubMed research, NICE guidelines, and NHS guidance.
Read moreArticleMatt — Gila3/9/2026
Oral GLP-1 Pills 2026: Wegovy, Foundayo, and Orforglipron Compared
Three oral GLP-1s now have FDA approval: Wegovy pill ($675/mo, Dec 2025), Foundayo orforglipron ($149/mo, April 2026), and Rybelsus (off-label). Trial data shows oral matches injection efficacy within 1-3pp. Here is the full comparison: efficacy, dose timing, side effects, cost.
Read more
ArticleAda — Gila3/9/2026
The Ozempic Personality: Why GLP-1s Change More Than Your Weight
Beyond appetite suppression, GLP-1 medications modulate reward circuits across the brain — reducing food cravings, alcohol consumption, and even compulsive behaviors. This article explores the identity transformation that follows: food grief, phantom fat, social identity shifts, and the impostor syndrome of a changed body. Backed by research from JAMA Psychiatry (107,000+ participants), The Lancet, Psychology Today, and the Endocrine Society. Includes guidance on when to seek professional support.
Read moreArticleMatt — Gila3/9/2026
The Second Year Is Where It Breaks: GLP-1 Persistence, Explained
One-year GLP-1 persistence has roughly doubled since 2021 — but only about one in seven people is still on therapy at two years. This evidence-based analysis examines the six reasons people stop (side effects, cost, supply shortages, unrealistic expectations, premature cessation, and lack of support structure) and the clinically-grounded strategies for staying on track, including the Weekly Plateau Scoreboard, the Rebound Early-Warning Threshold, and structured side effect management. Anchored by STEP 4 trial data showing a 14.8 percentage point difference between continuing and stopping.
Read moreArticleAda — Gila3/9/2026
What Is Food Noise? The Science Behind GLP-1s and Quiet Minds
Food noise is the constant, intrusive mental chatter about food that millions experience daily. This deep dive explains the neuroscience of how GLP-1 medications like semaglutide and tirzepatide quiet food noise by modulating the hypothalamus and reward pathways, distinguishes food noise from physiological hunger, and provides three evidence-based strategies — trigger-food visibility friction, small-plate pacing, and anchor meal templates — for managing it. Backed by research from JAMA, Cleveland Clinic, and NHS guidance.
Read more
ArticleThe Guardian Health3/6/2026
Weight-loss drugs alone will not solve UK’s obesity crisis, says Chris Whitty
The UK's Chief Medical Adviser, Chris Whitty, offers a critical perspective, reminding us that while GLP-1 medications are powerful tools, they're not a standalone solution for the obesity crisis. This emphasizes that lasting success on our journey integrates these incredible tools with essential lifestyle changes and a commitment to creating healthier food environments for long-term well-being!
Read more
ArticleThe Guardian Health3/6/2026
Weight-loss jab could be made for $3 a month, study finds
A groundbreaking study reveals that semaglutide, the powerful ingredient in Ozempic and Wegovy, could potentially be manufactured for just $3 a month as global patents expire! This fantastic news means these life-changing medications could soon become vastly more affordable and accessible to millions around the world, opening doors to better health and supporting our global community in the fight against obesity and diabetes.
Read more
ArticleSTAT News3/6/2026
Novo Nordisk's Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
New research shows that generic versions of semaglutide could be produced for just $3 a month, potentially transforming access in low- and middle-income countries. Patents are set to expire in India, China, Canada, Brazil, and Turkey this year. This isn't just about affordability — it's about ensuring that more of our global community gets the chance to experience the freedom and health improvements that GLP-1s can bring, regardless of where they live!
Read more
ArticleCentral Oregon Daily3/6/2026
GLP-1 price cuts announced for Wegovy, Ozempic
Here's some really encouraging news: Novo Nordisk just announced they're cutting the list prices for Wegovy and Ozompic to $675 per month starting in 2027. While insurance coverage still matters, this is a meaningful step toward making your GLP-1 journey more affordable and accessible. We've been cheering for solutions that help more of our community members access these life-changing medications, and price reductions are a big part of that picture!
Read more
ArticleX/Twitter3/5/2026
Ozempic may reduce the mortality risk from colon cancer — GLP-1 users were less than half as likely to die within 5 years
Dr. Rhonda Patrick dropped some groundbreaking news, showing GLP-1s like Ozempic might slash colon cancer mortality risk by over 50%! This isn't just about the scale, folks; it's a powerful reminder of the deep, systemic health benefits these medications can offer for our long-term well-being.
Read more
ArticleDrugs.com3/5/2026
Zepbound vs Mounjaro: Comparison Guide for Weight Loss and Diabetes Treatment
Drugs.com published a fantastic comparison of Zepbound and Mounjaro! This deep dive is crucial for understanding the nuances of these powerful tools, whether you're already on one or exploring which might be the best fit for your unique journey. Knowledge is power, team!
Read more
ArticleThe Guardian Health3/4/2026
Weight loss drugs may stop people getting addicted to drugs and alcohol, study finds
Incredible new research suggests GLP-1 medications could offer an exciting additional benefit: potentially reducing the risk of addiction to alcohol and drugs! This glimpse into how these medicines influence our brain's reward pathways is truly groundbreaking. It highlights the expanding positive impact these tools might have on our overall wellness journey as more is understood.
Read more
ArticleScienceDaily3/4/2026
Ozempic-like weight loss drugs may help the heart recover after a heart attack
Get this – new research shows GLP-1 medications might actually help your heart recover after a heart attack by boosting blood flow in those tiny vessels! This isn't just about the scale; it's exciting news for your overall cardiovascular health and highlights another incredible benefit of these medications for us.
Read more
ArticleMedPage Today3/2/2026
GLP-1 Drugs May Work Differently in Women
A new meta-analysis highlights that women on GLP-1 medications tend to experience greater average weight loss than men, likely due to biological differences like hormones. This insight reminds us that our bodies respond uniquely, but the powerful benefits of GLP-1s, combined with consistent effort, are making incredible strides for everyone on this journey!
Read more
ArticleNoom3/1/2026
GLP-1 Side Effects: What to Expect & How to Manage Them
Understanding potential GLP-1 side effects is key to a smooth journey! This Noom guide gives us excellent, practical tips on what to expect and, more importantly, how to proactively manage them. Let's empower ourselves with this knowledge to stay on track!
Read more
ArticleUVA Health3/1/2026
How to Tame GLP-1 Side Effects: 6 Tips
Nausea, constipation, and GI changes are real — and you're not alone if you've experienced them. UVA Health just shared six powerful tips for managing these side effects: eat slowly, stay hydrated, avoid strong smells, rotate injection sites, and give your body time to adjust. Most people find that side effects improve with these strategies and proper support. Your comfort matters, and you deserve to feel your best on this journey!
Read more
ArticlePsychology Today2/28/2026
GLP-1s and the Thin Ideal
Psychology Today highlights a crucial point: while GLP-1s are powerful tools, we must actively guard against the cultural pressure of the "thin ideal" and prioritize our mental health. It's so important to focus on a healthy relationship with our bodies and self-worth, rather than just chasing a number, to ensure a truly sustainable and joyful journey!
Read more
VideoStrong and Steady with Betty2/28/2026
Week 57: I Was Afraid to Share This | GLP-1 Update (95 lbs down)
You HAVE to watch Strong and Steady with Betty this week! She's down an incredible 95 lbs and shares the raw, honest truth about the mental and physical uncertainty of entering the maintenance phase. This video is a must-watch to feel less alone as we navigate this powerful journey together!
Read more
VideoBazgha Khalid, MD2/27/2026
Weight loss stall on GLP-1? Weight Loss Doctor Explains Hidden Insulin Resistance
If your GLP-1 journey has hit a frustrating plateau, you have to watch this video. Dr. Bazgha Khalid, an obesity medicine expert, dives deep into the often-missed link between weight loss stalls and hidden insulin resistance, explaining how to test for it and what strategies can finally get the scale moving again for us!
Read more
VideoJack Cooper2/27/2026
Retatrutide Explained: Benefits, Risks & New Data
If you're hearing the buzz about Retatrutide, Jack Cooper's video is an absolute must-watch! He breaks down the science, clinical data, benefits, and potential side effects so we can all get the full, evidence-based picture. Don't form an opinion until you've seen this – it's crucial for staying informed on your journey!
Read more